Olivier Catalani

发表

Comparison of subcutaneous versus intravenous administration of rituximab as maintenance treatment for follicular lymphoma: results from a two-stage, phase IB study.

A. Salar, R. Bouabdallah, G. Follows, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Obinutuzumab or Rituximab Plus CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma: Final Results from an Open-Label, Randomized Phase 3 Study (GOYA)

J. Burke, L. Sehn, I. Flinn, 2016 .

Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study

C. Négrier, G. Young, M. Callaghan, 2020, Thrombosis and Haemostasis.

Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial.

G. Gaidano, A. Delmer, M. Trněný, 2016, The Lancet. Haematology.

Pharmacokinetics, safety, and effi cacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial

G. Gaidano, A. Delmer, M. Trněný, 2016 .

Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia.

G. Gaidano, A. Delmer, P. Sayyed, 2015, British journal of clinical pharmacology.

Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study.

J. Oldenburg, C. Hermans, V. Jiménez‐Yuste, 2023, The Lancet. Haematology.

Emicizumab Prophylaxis in Adolescent/Adult Patients with Hemophilia A Previously Receiving Episodic or Prophylactic Bypassing Agent Treatment: Updated Analyses from the HAVEN 1 Study

J. Oldenburg, C. Kempton, M. Mancuso, 2017 .

Determining meaningful health‐related quality‐of‐life improvement in persons with haemophilia A using the Haemophilia Quality of Life Questionnaire for Adults (Haem‐A‐QoL)

M. Lehle, E. Asikanius, S. von Mackensen, 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

Use of Bypassing Agents Prior to and Post Bypassing Agent Dosing Guidance during Emicizumab Prophylaxis: Analyses from the HAVEN 1 Study

J. Oldenburg, C. Négrier, J. Mahlangu, 2017 .

Emicizumab Prophylaxis in Persons with Mild or Moderate Hemophilia A: Results from the Interim Analysis of the HAVEN 6 Study

J. Oldenburg, C. Hermans, V. Jiménez‐Yuste, 2021, Blood.

Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial

M. Konopleva, J. Cavenagh, G. Martinelli, 2022, Blood advances.

MIRROS: a randomized, placebo-controlled, Phase III trial of cytarabine ± idasanutlin in relapsed or refractory acute myeloid leukemia.

J. Esteve, M. Konopleva, G. Martinelli, 2020, Future oncology.

First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial.

R. Kreienberg, W. Jonat, N. Harbeck, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma.

J. Burke, L. Sehn, I. Flinn, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.